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Background: Multiplex assays are available to measure an array of circulating chemokines, soluble cytokine
receptors and growth factors. However, there is limited information regarding whether these analytes are
suitable for large-scale epidemiological studies to assess their relationships with chronic diseases, including
cancer. 
Methods: We examined detectability, assay repeatability, and 3-year within-subject reproducibility of plasma
levels of 25 chemokines and 11 soluble receptors of cytokines and growth factors selected from the Human
Millipore Panels. Plasma samples were obtained from 36 men (average age 62 years) and 17 women (average
age 32 years) who participated in two epidemiological studies. Inter-assay and within-subject reproducibility
were assessed by intraclass correlation coefﬁcients (ICC). 
Results: All analytes, except lymphotactin (47% detectability), were detectable in > 90% of plasma samples.
Inter-assay reproducibility for all analytes in 36 men tested three times on separate days were good to
excellent (ICCs: 0.71–1.00). Within-subject reproducibility in 17 women sampled three times in three years
were excellent (ICC ≥ 0.75) for ﬁve chemokines (eotaxin, fractalkine, 6Ckine, eotaxin 3, and SDF-1 α+ β) and
three soluble receptors (sIL-1R2, sIL-4R and sVEGFR2); ICCs were fair to good (0.4 ≤ ICC < 0.75) for 15
chemokines and eight soluble receptors. However, ﬁve chemokines (GRO, IP-10, MIP-1 β, BCA-1, and MIP-3 α)
had ICC < 0.4, suggesting biological variability. 
Conclusion: Multiplex assays for plasma levels of selected chemokines and soluble receptors showed good
to excellent assay detectability and repeatability. Most analytes also had good 3-year within-subject repro-
ducibility, indicating that a single measurement of these analytes may be used to assess biomarker-disease
associations. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 1. Introduction 
Increasing evidence suggests that chronic inﬂammation is associ-
ated with risk of several cancers [ 1 –4 ]. Chronic inﬂammation may be
involved in cancer initiation, promotion, and progression via several
mechanisms. Activated inﬂammatory cells produce reactive oxygen 
 
 
     
* Correspondence to: Department of Epidemiology and Population Health, Albert 
Einstein College of Medicine, 1300 Morris Park Avenue, Belfer Building, Room 1315-B, 
Bronx, NY 10461, USA. Tel.: + 1 718 430 2929; fax: + 1 718 430 8780. 
E-mail address: ilir.agalliu@einstein.yu.edu (I. Agalliu). 
 
 
 
 
 
 
2211-2839 c © 2013 The Authors. Published by Elsevier B.V. 
http://dx.doi.org/10.1016/j.rinim.2013.07.001 
Open access under CC BY-NC-ND licand nitrogen species, which create a mutagenic environment enabling
genome instability that leads to tumor initiation [ 5 ]. Growth factors
and cytokines produced by the inﬂammatory cells further induce pro-
liferation and suppress apoptosis of cancer cells and hence promote
growth of primary tumors [ 4 , 6 , 7 ]. Inﬂammatory cells also produce
various pro-inﬂammatory chemokines, a group of chemo-attractant
cytokines which, in addition to recruiting leukocytes to inﬁltrate the
local inﬂammatory site, may act as angiogenic factors or growth fac-
tors that further stimulate tumor progression [ 8 –12 ]. 
However, to maintain tissue homeostasis, there are anti-
inﬂammatory and anti-tumor immune mediators. For example, some
chemokines are anti-inﬂammatory and induce inﬁltration of anti-
tumor effectors (e.g., Th1 lymphocytes and natural killer cells) and / orense.
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dave angiostatic functions [ 10 , 13 ]; soluble receptors of proinﬂamma- 
ory cytokines and growth factors could act as decoy receptors, block 
inding of their ligands to membrane receptors, and hence inhibit 
igand signaling [ 14 –16 ]. 
Despite the importance of host immunity in carcinogenesis, most 
pidemiologic studies have focused on cancer association with a few 
nﬂammation markers, mostly IL-6 and TNF- α [ 17 –19 ]. There is a need 
o examine other pro- and anti-tumorigenic immune response mark- 
rs in order to better understand their roles in cancer etiology. Such 
pidemiological studies can be facilitated by multiplex assays mea- 
uring an array of immune response mediators, such as cytokines, 
hemokines, soluble receptors of cytokines and growth factors, in 
lasma or serum. Before embarking on large prospective epidemio- 
ogic studies, it is important to examine assay performance of these 
nalytes in terms of detectability and inter-assay reproducibility. It 
s also crucial to assess the within-person variability of immune re- 
ponse markers over time to determine whether the circulating levels 
f a marker are relatively stable, hence a single measurement of the 
arker can reﬂect an individual’s level in the long run. 
Several studies have evaluated the performance and / or within- 
ubject reproducibility of circulating levels of cytokines, chemokines 
nd soluble receptors in healthy individuals [ 20 –28 ]. However, the 
ajority of these studies have examined a small number of mak- 
rs (e.g., IL-1Ra, IL-2, IL-5, IL-6 and TNF- α). Two studies assessed the 
ithin-subject variability of more than 20 immune response markers 
ver a period of 2–3 years, but not the assay performance [ 24 , 28 ]. A 
arge methodological study recently evaluated the assay performance 
f 116 inﬂammation, immune, and metabolic markers among 100 
ancer-free participants in the Prostate, Lung, Colorectal and Ovar- 
an Cancer (PLCO) Trial across different platforms and different sam- 
les: serum, heparin or EDTA [ 25 ]. Although this study showed that 
hese biomarkers had good performance in plasma samples, they did 
ot evaluate the within-subject reproducibility of these markers over 
ime. 
The goal of our study was to examine both assay performance 
detectability and inter-assay reproducibility) and within-subject re- 
roducibility over a 3-year period of plasma levels of 25 chemokines 
nd 11 soluble receptors of cytokines and growth factors selected 
rom the multiplex panels of Millipore (Billerica, MA). We focused 
n chemokines and soluble receptors rather than the traditional cy- 
okines (e.g., interleukins and interferon), because the majority of 
ytokines have very low circulating levels in healthy individuals [ 25 ]. 
e report here that the chemokines and soluble receptors selected for 
his study have excellent detectability and inter-assay reproducibil- 
ty, and the majority of them have good to excellent within-subject 
eproducibility over a 3-year period. 
. Materials and methods 
.1. Selection of chemokines and soluble receptors 
The Millipore’s Human Cytokine / Chemokine Panels I, II, and III 
Billerica, MA) consist of a total of 76 analytes in three multiplex kits, 
nd 46 of them are chemokines. The Milliplex Human Soluble Cy- 
okine Receptor panel assays for 14 soluble receptors of cytokines 
nd growth factors. We selected 25 chemokines and 11 soluble re- 
eptors from these four panels to be examined for this study, because 
etectable levels of these markers were reported in > 75% of plasma 
amples from healthy individuals by either Millipore (Millipore per- 
onal communication) or by the methodological study of Chaturvedi 
t al. [ 25 ]. Our study objectives were to conﬁrm detectability and 
ssess inter-assay reproducibility and 3-year within-subject repro- 
ucibility of these immune response biomarkers. 2.2. Study design and laboratory assay 
We conducted two separate studies to evaluate assay performance 
and 3-year within-subject reproducibility. 
2.2.1. Study 1 for assay performance 
EDTA plasma samples were obtained from a random sample of 36 
men with no previous history of any cancer who were recruited as 
controls from general practitioners’ ofﬁces and provided a single non- 
fasting blood sample as part of a prostate cancer case-control study 
conducted in the Bronx, New York from 1998 through 2000 [ 29 ]. 
Blood was collected in purple-top EDTA tubes and processed within 
an hour of blood draw at biorepository of the Albert Einstein College 
of Medicine. The EDTA plasma samples were stored in 2 mL aliquots 
at −75 ◦C. The plasma samples were assayed for the chemokines and 
soluble receptors three times, each on a separate day in the same 
laboratory by the same technician. Detectability of an immune re- 
sponse marker was deﬁned as the proportion of samples with values 
above the assay limit of detection (LOD). Inter-assay intraclass cor- 
relation coefﬁcient (ICC) was calculated for each marker to evaluate 
inter-assay reproducibility when the marker was measured repeat- 
edly in the same blood sample. Mean age of the 36 men was 61.8 
years (range: 46–79), and their racial / ethnic distribution was 55.6% 
African American, 19.4% Hispanic, and 25% others. 
Of the 11 soluble receptors selected, the inter-assay reproducibil- 
ity for sgp130, sIL-6R, sIL-1R2, and sTNFR1, as measured by coefﬁcient 
of variation (CV), was previously evaluated, and therefore was not as- 
sessed in Study 1. For these soluble receptors, inter-assay CVs were 
obtained as follows: aliquots from the same four control samples were 
inserted in the assay plates testing 1478 study samples of a colorectal 
cancer study; 42 assay plates were run over several months in the 
same laboratory by the same technician. For each control sample, the 
four soluble receptors were measured 42 times, and the inter-assay 
CV for a soluble receptor was calculated as standard deviation divided 
by the mean of 42 measurements. The average inter-assay CVs over 
the four control samples were 6.6% for sgp130, 5.5% for sIL-6R, 7.1% 
for sIL-1R2, and 5.9% for sTNFR1 (unpublished data). 
2.2.2. Study 2 for within-subject reproducibility 
Three fasting blood samples were collected at baseline in 2002 
and at the year-1 and year-3 visits from 17 women, who partici- 
pated in the Bronx / Manhattan site (New York) of the multicenter 
Women’s Interagency HIV study (WIHS) [ 30 , 31 ]. Within 6 h after col- 
lection, blood tubes were centrifuged at room temperature and citrate 
plasma aliquots (1 mL each) were stored at −70 ◦C. For this study, the 
samples were assayed for levels of the 25 chemokines and 11 soluble 
receptors. All three samples of an individual were assayed together on 
the same assay plate, avoiding the issue of calibration over time. For 
each marker, 3-year ICC was calculated to assess the within-subject 
reproducibility of marker level when the individual was sampled re- 
peatedly over time. The 17 women were HIV-negative at baseline and 
follow-up visits, and did not have a history of hepatitis B or C infection 
[ 31 ]. They were on average 32.3 years of age at baseline (range: 19–47 
years), and 65% were African-American. 
2.2.3. Laboratory assays 
Milliplex human cytokine / chemokine Panels I, II and III were 
used to measure plasma levels of the 25 chemokines, and the Milliplex 
human soluble cytokine receptor panel was used for the 11 soluble 
receptors (Millipore, Billerica, MA) according to manufacturer’s in- 
structions. These multiplex assays use the nonmagnetic polystyrene 
bead-based Luminex xMAP technology. Since Chaturvedi and col- 
leagues [ 25 ] demonstrated that assays performance for the Milliplex 
human cytokine / chemokine panels was better in plasma in compar- 
ison to serum samples, we decided to run the assays for these two 
studies on plasma samples. All laboratory measurements were done 
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Table 1 
Inter-assay ICCs of measuring chemokines and soluble receptors in 36 samples tested three times on separate days. 
Minimum detectability 
(%) in 3 tests a 
Median (IQR b ) Day 1 
(pg / mL) 
Median (IQR b ) Day 2 
(pg / mL) 
Median (IQR b ) Day 3 
(pg / mL) Inter-assay ICC (95% CI) 
Milliplex human cytokine / chemokine Panel 
Panel I c 
Eotaxin / CCL11 100 65.4 (52.1–84.5) 66.8 (55.9–95.7) 72.1 (58.5–103) 0.96 (0.94–0.98) 
Fractalkine / CX3CL1 94 88.6 (47.6–181) 94.2 (58.0–207) 119 (80.4–252) 0.78 (0.65–0.87) 
GRO / CXCL1 100 489 (337–722) 551 (364–765) 537 (361–791) 0.98 (0.97–0.99) 
IL-8 / CXCL8 100 5.4 (2.9–9.9) 4.9 (3.1–10.6) 5.1 (2.9–11.4) 0.95 (0.92–0.97) 
IP-10 / CXCL10 100 278 (212–355) 320 (250–393) 340 (248–419) 0.94 (0.90–0.97) 
MCP-1 / CCL2 100 233 (205–336) 253 (217–336) 262 (224–340) 0.96 (0.92–0.98) 
MDC / CCL22 100 1027 (803–1250) 1083 (853–1282) 1190 (889–1467) 0.87 (0.79–0.93) 
MIP-1 β/ CCL4 100 27.2 (19.9–41.1) 26.2 (18.6–32.8) 31.3 (25.4–44.8) 0.86 (0.78–0.92) 
Panel II c 
BCA-1 / CXCL13 100 30.2 (22.0–38.5) 28.6 (19.7–34.9) 31.2 (21.6–39.3) 0.95 (0.92–0.97) 
CTACK / CCL27 100 620 (449–765) 638 (499–810) 568 (409–720) 0.93 (0.88–0.96) 
6Ckin / CCL21 97 499 (290–593) 481 (302–611) 489 (325–622) 0.98 (0.97–0.99) 
Eotaxin 2 / CCL24 100 376 (163–663) 323 (167–608) 363 (168–683) 0.99 (0.98–0.99) 
Eotaxin 3 / CCL26 94 23.7 (8.6–31.3) 16.2 (6.3–33.6) 18.1 (7.6–31.1) 0.86 (0.78–0.92) 
ENA-78 / CXCL5 100 440 (208–688) 418 (194–678) 454 (205–710) 1.00 (0.99–1.00) 
I-309 / CCL1 97 2.4 (1.8–4.3) 2.2 (1.6–4.6) 2.3 (1.8–4.4) 0.93 (0.88–0.96) 
MCP-2 / CCL8 100 17.2 (14.4–24.1) 16.5 (13.9–22.3) 14.4 (11.8–21.0) 0.88 (0.81–0.93) 
MIP-1d / CCL15 100 1901 (1310–2801) 1721 (1304–2325) 1967 (1443–2699) 0.98 (0.97–0.99) 
SDF-1 α+ β/ CXCL12 100 2278 (1705–2874) 2468 (1962–3093) 2081 (1758–2527) 0.96 (0.94–0.98) 
TARC / CCL17 100 32.2 (18.3–41.8) 33.2 (17.3–39.8) 32.6 (18.5–40.7) 0.98 (0.97–0.99) 
Panel III c 
GCP-2 / CXCL6 100 44.4 (32.3–51.7) 44.0 (32.3–51.6) 51.1 (39.2–58.8) 0.94 (0.90–0.97) 
I-TAC / CXCL11 100 34.0 (18.8–48.2) 30.8 (19.4–46.0) 37.0 (21.3–55.3) 0.99 (0.98–0.99) 
Lymphotactin / XCL1 47 13.7 (4.5–46.3) 5.2 (5.1–34.3) 17.8 (8.9–37.2) 0.71 (0.56–0.83) 
MIG / CXCL9 100 734 (397–1086) 798 (402–1057) 830 (468–1277) 0.98 (0.97–0.99) 
MIP-3 α/ CCL20 100 11.0 (7.0–14.5) 12.1 (7.6–14.8) 11.0 (6.8–16.0) 0.98 (0.97–0.99) 
MIP-3 β/ CCL19 100 70.5 (53.8–114) 77.3 (59.6–108) 87.7 (65.0–132) 0.91(0.86–0.95) 
Milliplex human soluble cytokine receptor Panel d 
sCD30 100 82.5 (39.3–150) 68.2 (45.5–124) 84.3 (37.8–180) 0.83 (0.73–0.90) 
sEGFR 100 81,810 (72,797– 88,860) 81,840 (71598–88,901) 80,378 (73,298–90,038) 0.95 (0.91–0.97) 
sIL-2R α 100 675 (509–937) 720 (525–980) 659 (513–927) 0.98 (0.97–0.99) 
sIL-4R 100 954 (822–1203) 1140 (968–1405) 1041 (89 –1257) 0.97 (0.94–0.98) 
sVEGFR1 100 1989 (1047–3243) 1758 (867–2901) 1463 (743–2181) 0.93 (0.88–0.96) 
sVEGFR2 100 16,881 (15,488–18,108) 17,107 (15,193–18,774) 16,450 (14,941–18,243) 0.93 (0.89–0.96) 
sVEGFR3 100 4328 (2674–8065) 4016 (3002–5910) 3598 (2216–7501) 0.74 (0.60–0.85) 
a Detectability is deﬁned as the percent of 36 samples that had analyte levels above the assay limit of detection (LOD); the minimum detectability of the three tests in three separate 
days is reported here. 
b IQR— inter-quartile range. 
c For chemokines, the most commonly used name is listed ﬁrst, followed by the name based on the new nomenclature. 
d The inter-assay reproducibility, as measured by CVs, for sgp130, sIL-1R2, sIL-6R, and sTNFR1 had previously been evaluated and not assessed in Study 1 (see Section 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 at the Laboratory for Clinical Biochemistry Research at the University
of Vermont according to the manufacturer’s protocols. Study samples
were tested in duplicate and the duplicate measurements were aver-
aged for statistical analysis. The laboratory staff that conducted the
experimental assays was blinded to the samples IDs and replicates.
Studies were approved by the Institutional Review Board (IRB) of the
Albert Einstein College of Medicine and written informed consents
were obtained from participants in each of the two studies [ 29 –31 ]. 
2.2.4. Statistical analysis 
The distributions of plasma levels of the 25 chemokines were
skewed, hence values were log-transformed, whereas the distribu-
tions of soluble receptors were normal. To be consistent in presenting
the data, we report the medians and inter-quartile ranges (IQRs) for
all the analytes in Tables 1 and 2 . For samples with an undetectable
level below the assay limit of detection (LOD), their values were im-
puted using 1 2 × LOD of that analyte [ 32 , 33 ]. One-way random effects
ANOVA models were used to calculate the inter-assay ICCs for assay
reproducibility in Study 1, as well as the 3-year ICCs for within-subject
reproducibility in Study 2. In this model, the total variance of a marker
value ( σ T 
2) was separated into three components: (i) between-subject
variance ( σG 
2 ), (ii) intra-individual variance ( σ I 
2 ), and (iii) analyticresidual variance ( σA 
2 ). The proportion of total variance attributable
to between-subject, intra-individual and analytic variation was an-
notated as R G, R I, and R A , respectively (e.g., R G = σG 2 / σ T 2 ). Analytic
variation was based on within-run variance from samples assayed in
duplicate, hence R A ( σA 
2 / σ T 
2 ) tended to be negligible. We eliminated
σA 
2 by using the average of the duplicate measurements. As such σ T 
2
= σG 2 + σ I 2 . The ICC for each chemokine and soluble receptor was
estimated by σG 
2 / σ T 
2 [ 34 ]. We used mixed effects models to ex-
amine if analytes were also associated with women’s characteristics
including age at each visit, race (black vs. other), BMI, smoking sta-
tus at baseline (current smoker vs. non-smoker) and white blood cell
(WBC) counts (log-transformed value) at each blood draw in study 2.
Since circulating levels of majority of chemokines and soluble recep-
tors were not associated with women’s characteristics or WBC counts,
we present the unadjusted ICCs throughout the manuscript. 
3. Results 
Table 1 provides the results of Study 1, assessing detectability
and inter-assay ICCs of the chemokines and soluble receptors assayed
three times in separate days at the same laboratory. As observed, these
analytes were detectable in all plasma samples with the exception of
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Table 2 
Three-year ICCs of chemokines and soluble receptors among 17 women sampled at baseline, year 1 and year 3. 
Milliplex human 
cytokine / chemokine 
Panel Baseline Year 1 Year 3 3-Year Overall 
Median (IQR a ) pg / mL Median (IQR a ) pg / mL Median (IQR a ) pg / mL ICC 95% CI 
Panel I b 
Eotaxin / CCL11 35.7 (23.3–60.9) 37.1 (24.6–52.3) 43.1 (25.1–89.1) 0.76 0.56–0.90 
Fractalkine / CX3CL1 175 (119–201) 190 (132–240) 191 (132–253) 0.77 0.57–0.90 
GRO / CXCL1 407 (345–521) 388 (302–538) 395 (330–559) 0.21 −0.07 to 0.54 
IL-8 / CXCL8 396 (51–944) 314 (79.7–1427) 362 (40.7–865) 0.44 0.14–0.71 
IP-10 / CXCL10 74.2 (52.2–119) 87.1 (72.0–124) 91.2 (80.9–123) 0.03 −0.20 to 0.37 
MCP-1 / CCL2 98.1 (57.4–162) 110 (73.3–240) 97.8 (72.6–143) 0.40 0.11–0.69 
MDC / CCL22 607 (438–703) 552 (414–853) 619 (426–744) 0.58 0.30–0.80 
MIP-1 β/ CCL4 15.2 (11.1–25.6) 15.8 (12.7–19.8) 20.4 (13.4–25.1) 0.25 −0.03 to 0.58 
Panel II b 
BCA-1 / CXCL13 20.7 (16.3–66.0) 22.0 (15.4–27.7) 23.2 (17.4–25.0) 0.32 0.02–0.63 
CTACK / CCL27 137 (109–183) 167 (133–208) 161 (126–190) 0.73 0.50–0.88 
6Ckine / CCL21 469 (375–615) 511 (400–683) 463 (426–605) 0.86 0.72–0.94 
Eotaxin 2 / CCL24 93.8 (57.6–156) 112 (81.9–220) 138 (74.8–200) 0.58 0.31–0.80 
Eotaxin 3 / CCL26 35.1 (27.9–46.5) 35.7 (24.6–45.8) 32.7 (24.6–35.9) 0.84 0.69–0.93 
ENA 78 / CXCL5 458 (307–555) 650 (282–947) 654 (403–704) 0.71 0.48 – 0.87 
I-309 / CCL1 5.0 (4.1–5.9) 5.7 (4.2–6.4) 4.8 (3.9–5.5) 0.67 0.42–0.85 
MCP-2 / CCL8 18.6 (17.1–21.1) 19.0 (16.5–22.2) 18.2 (14.8–20.3) 0.65 0.40–0.84 
MIP-1d / CCL15 829 (660–1152) 1370 (760–1774) 886 (825–1311) 0.66 0.42–0.85 
SDF-1 α+ β/ CXCL12 1186 (1073–1483) 1265 (1102–1529) 1414 (1186–1464) 0.82 0.65–0.92 
TARC / CCL17 17.5 (16.1–26.0) 21.5 (16.9–35.9) 27.4 (18.1–32.6) 0.52 0.24–0.77 
Panel III b 
GCP-2 / CXCL6 22.9 (17.3 – 30.0) 28.5 (20.7 – 36.3) 30.7 (24.7 – 35.8) 0.63 0.36 – 0.83 
I-TAC / CXCL11 27.8 (19.0–34.5) 25.0 (13.6–41.4) 36.3 (24.0– 43.3) 0.52 0.24– 0.77 
Lymphotactin / XCL1 23.6 (7.4–30.9) 23.6 (23.5–43.0) 34.5 (23.6–43.0) 0.58 0.30–0.80 
MIG / CXCL9 219 (138–278) 194 (149–287) 193 (162–326) 0.43 0.13–0.71 
MIP-3 α/ CCL20 6.1 (4.6–9.4) 10.5 (5.2–17.0) 10.5 (7.5–14.3) 0.05 −0.19 to 0.39 
MIP-3 β/ CCL19 35.0 (26.0–47.9) 40.5 (33.8–51.9) 39.8 (32.7–52.1) 0.46 0.17–0.73 
Milliplex human 
soluble cytokine 
receptor Panel 
Median (IQR b ) pg / mL Median (IQR b ) pg / mL Median (IQR b ) pg / mL ICC 95% CI 
sCD30 230 (176–352) 224 (144–288) 276 (112–336) 0.50 0.21–0.75 
sEGFR 52,756 (48,014–58,685) 54,594 (47,731–60,855) 50,498 (45,873–54,982) 0.42 0.12–0.70 
sgp130 99,703 
(86,758–106,774) 
102,859 
(84,526–123,977) 
100,214 
(79,286–116,218) 
0.63 0.37–0.83 
sIL-1R2 5664 (4279–7609) 5412 (4552–6904) 4875 (4016–7482) 0.78 0.58–0.90 
sIL-2R α 1091 (933–1212) 1249 (832–1360) 999 (759–1301) 0.56 0.28–0.79 
sIL-4R 1268 (1135–1423) 1212 (1128–1524) 1257 (1135–1372) 0.86 0.72–0.94 
sIL-6R 12,179 (9551–14,199) 12,451 (9310–13,951) 10,861 (9398–13,905) 0.52 0.24–0.77 
sTNFR1 1072 (896–1217) 1156 (957– 1382) 1039 (951–1205) 0.65 0.40–0.84 
sVEGFR1 8835 (7036–10,997) 9126 (6561–10,997) 9391 (4552–13,163) 0.58 0.30–0.80 
sVEGFR2 10,300 (8664–12,430) 10,909 (9596–12,192) 10,065 (8897–11,425) 0.79 0.59–0.91 
sVEGFR3 8717 (6180–13,542) 8445 (5484–11,934) 9579 (4611–12,738) 0.71 0.48–0.87 
a IQR—inter-quartile range. 
b For chemokines, the most commonly used name is listed ﬁrst, followed by the name based on the new nomenclature. 
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Mymphotactin (XCL1), which was detectable in no more than 47% of 
amples from three separate tests. All analytes had good to excellent 
nter-assay ICCs ranging from 0.71 to 1.00. 
The medians (IQR) of the chemokines and soluble receptors in 17 
omen sampled three times over a 3-year period (Study 2) as well as 
-year ICCs and 95% CIs for within-subject reproducibility are shown 
n Table 2 . Lymphotactin also had a low detectability in Study 2, with 
9% of the samples had levels above LOD. All the other analytes were 
etectable. As seen in Table 2 , the majority of these analytes had good 
o excellent within-subject reproducibility (i.e. low variability). Five 
hemokines (eotaxin, eotaxin 3, fractalkine, 6Ckine, and SDF-1 α+ β) 
nd three soluble receptors (sIL1-R2, sIL-4R and sVEGFR2) showed 
xcellent within-subject reproducibility (ICC ≥ 0.75), 15 chemokines 
nd eight soluble receptors had fair to good within-subject repro- 
ucibility (0.4 ≤ ICC < 0.75), whereas ﬁve chemokines (GRO, IP-10, 
IP-1 β, BCA-1, and MIP-3 α) had poor reproducibility (ICC < 0.4). 4. Discussion 
There has been a lot of interest in evaluating the role of circulating 
levels of cytokines, chemokines and soluble receptors in the etiol- 
ogy of chronic diseases, including cancer. However, there is paucity 
of information regarding the assay performance for these analytes 
and whether their levels are stable over time. Moreover, there are 
no established clinical reference values for these biomarkers that can 
be used in etiologic studies. For prospective epidemiologic studies, 
it is important to ﬁrst demonstrate that these biomarkers (a) can be 
detectable in healthy individuals, (b) have excellent laboratory repro- 
ducibility, and (c) have reasonable reproducibility of measurements 
over a long period of time, which can indicate that a single measure- 
ment of these markers in plasma / serum can be used to assess their 
associations with chronic diseases.. 
In this study, we evaluated detectability, inter-assay reproducibil- 
ity and three-year within-subject reproducibility of chemokines and 
soluble receptors selected from the Millipore panels. In Study 1, we 
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 conﬁrmed the detectability of the selected chemokines (except lym-
photactin) and soluble receptors. The high detectability of these ana-
lytes was expected, however, as these chemokines and soluble recep-
tors were selected based on their detectability of > 75% in plasma sam-
ples from healthy individuals in other laboratories (Millipore personal
communication and the study of Chaturvedi et al. [ 25 ]. Four soluble
receptors (sgp130, sIL-6R, sIL-1R2, and sTNFR1) were not evaluated
in Study 1, because they had previously been examined in a colorectal
cancer study conducted by our group, and all of them were detected
in > 99% of 1478 plasma samples (unpublished data). We used the de-
tectability cutoff point of > 75% to determine that an analyte is suitable
to be examined as an exposure / predictor variable in epidemiological
studies, because individuals with an undetectable level can be cate-
gorized in the lowest quartile group in data analyses. The multiplex
assays for these chemokines and soluble receptors had shown good
inter-assay reproducibility, with inter-assay ICCs > 0.70 for all the 25
chemokines and 7 soluble receptors. For the four soluble receptors
not evaluated in Study 1 (sgp130, sIL-6R, sIL-1R2, and sTNFR1), their
inter-assay CVs obtained from our previous study ranged from 5.5%
to 7.1%. 
Although we found good laboratory assay performance for 24
chemokines (excluding lymphotactin) and all 11 soluble receptors
considered in this study, not all of them are suitable for epidemiolog-
ical studies based on their within-subject reproducibility. The 3-year
ICCs were ≥ 0.4 for all soluble receptors and for 80% (20 out of 25)
of the chemokines. However, ﬁve chemokines (GRO, IP-10, MIP-1 β,
BCA-1, and MIP-3 α) had an ICC < 0.4, suggesting their circulating lev-
els tend to vary from time to time; hence multiple serial samples over
time may be necessary to reﬂect an individual’s exposure status to
these chemokines. The ICC cutoff point of ≥0.4, which we deemed as
acceptable in this study, is comparable to the ICCs of some common
epidemiological biomarkers, such as serum triglycerides (ICC = 0.5)
[ 35 ] and estradiol (ICC = 0.45) [ 36 ]. 
There are a few studies that have assessed within-subject repro-
ducibility of chemokines and soluble receptors [ 22 , 24 , 28 ]. Two stud-
ies [ 22 , 24 ] that utilized blood samples of 30 premenopausal and 35
postmenopausal women of the New York University Women’s Health
Study collected over 3 years, evaluated within-subject reproducibility
of cytokines / chemokines, including fractalkine, MCP-1, MCP-2, MIP-
1 β, eotaxin, GRO- α, IP-10, sEGFR, sIL-6R and IL-8 that were assessed
in our study. They reported good to excellent within-subject repro-
ducibility (ICC > 0.60) for these chemokines with the exception of
IL-8, which had a 3-year ICC of 0.02. [ 22 , 24 ]. However, in our study,
we found overall fair to excellent within-subject reproducibility (ICC
range: 0.40–0.77) for IL-8, eotaxin, fractalkine, MCP-1, and MCP-2, but
poor reproducibility for, MIP-1 β, GRO- α and IP-10 (ICC range: 0.03–
0.25). In another study, Clendenen and colleagues [ 28 ] evaluated 1–3
years within-subject reproducibility (average two years apart) of 22
cytokines and soluble receptors among 18 female participants aged
42–62 years from the Northern Sweden Health and Disease study co-
hort. With regard to four analytes, which we also evaluated in our
study, they reported a very good reproducibility for IL-8 (ICC = 0.86),
sIL-2R (ICC = 0.86), and sIL-6R (ICC = 0.69), but low reproducibil-
ity for sTNFR1 (ICC = 0.31) [ 28 ]. In our study, all four analytes had
fair to good reproducibility (ICC range 0.44–0.65). Some of the dis-
crepancies observed between our results and those obtained from
previous studies [ 22 , 24 , 28 ] could be due to differences in study pop-
ulation, women’s demographic and lifestyle characteristics, length of
follow-up period, blood collection in relation to timing of menstrual
cycle or menopausal status as well as assay methods in each study.
However, a previous study [ 24 ] showed no inﬂuence of the menstrual
cycle or menopausal status of the women on the ICCs of cytokines or
chemokines. Thus, it is unlikely that differences in our results could
be due to variation in hormone levels.  
 Some studies have suggested that circulating levels of inﬂamma-
tory markers could vary by subjects’ demographic and lifestyle char-
acteristics including age, gender, race, obesity, smoking, and phys-
ical exercise [ 37 –39 ]. We examined whether circulating levels of
chemokines and soluble receptors were associated with women’s
age, race, BMI, smoking status and white blood cell count (a surrogate
marker of inﬂammation) in our Study 2 dataset. We did not see any
major difference in within-subject 3-year ICC when we adjusted the
model for these variables as ﬁxed effects in mixed models. Thus we
have presented the unadjusted ICCs values. Nevertheless, there were
only 17 women in Study 2 and the lack of association could be due to
small sample size. 
In conclusion, of the 25 chemokines and 11 soluble receptors se-
lected to be assessed in this study, 19 of the chemokines and all
soluble receptors are suitable to be evaluated as exposure / predictor
variables in epidemiological studies based on assay performance (de-
tectability > 75% and inter-assay reproducibility > 0.70) and 3-year
within-subject reproducibility (ICC ≥ 0.4). Lymphotactin has low de-
tectability. Five chemokines (GRO, IP-10, MIP-1 β, BCA-1, and MIP-3 α)
need to be assessed with caution in epidemiological studies due to
their low 3-year within-subject reproducibility. 
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